Tags

Type your tag names separated by a space and hit enter

A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Immunotherapy 2019; 11(11):937-944I

Abstract

Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects.

Authors+Show Affiliations

The Pennsylvania State University College of Medicine, Penn State University, 500 University Drive, Hershey, PA 17033, USA.The Pennsylvania State University College of Medicine, Penn State University, 500 University Drive, Hershey, PA 17033, USA.The Pennsylvania State University College of Medicine, Penn State University, 500 University Drive, Hershey, PA 17033, USA.Allergy, Asthma & Immunology, the Pennsylvania State University, College of Medicine, Department of Medicine and Pediatrics, 500 University Drive, Hershey, PA 17033, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31234673

Citation

Hwang, Gloria, et al. "A Review of Kallikrein Inhibitor Lanadelumab in Hereditary Angioedema." Immunotherapy, vol. 11, no. 11, 2019, pp. 937-944.
Hwang G, Johri A, Ng S, et al. A review of kallikrein inhibitor lanadelumab in hereditary angioedema. Immunotherapy. 2019;11(11):937-944.
Hwang, G., Johri, A., Ng, S., & Craig, T. (2019). A review of kallikrein inhibitor lanadelumab in hereditary angioedema. Immunotherapy, 11(11), pp. 937-944. doi:10.2217/imt-2018-0197.
Hwang G, et al. A Review of Kallikrein Inhibitor Lanadelumab in Hereditary Angioedema. Immunotherapy. 2019;11(11):937-944. PubMed PMID: 31234673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of kallikrein inhibitor lanadelumab in hereditary angioedema. AU - Hwang,Gloria, AU - Johri,Ansh, AU - Ng,Sally, AU - Craig,Timothy, Y1 - 2019/06/25/ PY - 2019/6/27/pubmed PY - 2019/6/27/medline PY - 2019/6/26/entrez KW - DX-2930 KW - bradykinin KW - hereditary angioedema KW - high-molecular-weight kininogen KW - kallikrein KW - lanadelumab SP - 937 EP - 944 JF - Immunotherapy JO - Immunotherapy VL - 11 IS - 11 N2 - Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor. Pharmacokinetics show a half-life of 14 days with a dose-dependent effect. Completed trials for lanadelumab include two Phase III studies with updated efficacy in preventing angioedema in hereditary angioedema patients. Ongoing data show the safety of the targeted therapy along with less frequent administration requirements. Information on long-term safety is still needed, as well as, further studies on the correlation of subcutaneous administered dosing requirements and severity of side effects. SN - 1750-7448 UR - https://www.unboundmedicine.com/medline/citation/31234673/A_review_of_kallikrein_inhibitor_lanadelumab_in_hereditary_angioedema_ L2 - http://www.futuremedicine.com/doi/full/10.2217/imt-2018-0197?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -